Zenotech Laboratories Ltd
₹42.84
(2.00%)
Wed, 18 Mar 2026, 00:03 am
Health Technology
Pharmaceuticals: Major
24.5KZenotech Laboratories Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 169.23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.32 | 0 | 13.86 | 24.79 | 43.47 | 56.45 |
| Price to book ratio | 3.90 | 5.31 | 2.55 | 2.75 | 4.03 | 2.50 | 2.09 | 2.74 | 17.48 | 0 | 0 | 0 | 5.91 | 3.33 | 1.81 | 4.41 | 4.35 | 3.49 | 3.98 | 3.30 |
| Price to sales ratio | 13.75 | 21.80 | 35.09 | 49.50 | 59.61 | 22.10 | 61.99 | 23.47 | 20.61 | 38.22 | 56.16 | 56.89 | 22.29 | 9.95 | 3.46 | 11.03 | 9.46 | 7.49 | 9.81 | 8.13 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 134.57 | 0 | 0 | 8.01 | 50.28 | 18.57 | 13.73 | 28.26 | 29.08 |
| Enterprise value | 1.98B | 3.11B | 2.48B | 2.82B | 3.81B | 1.56B | 1.11B | 871.61M | 973.32M | 2.04B | 1.7B | 1.79B | 2.19B | 1.37B | 1.07B | 2.32B | 3.11B | 2.76B | 3.41B | 2.9B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.05 | 70.07 | 23.14 | 16.47 | 25.56 | 27.97 |
| Debt to equity ratio | 0.94 | 0.63 | 0.16 | 0.15 | 0.09 | 0.05 | 0.09 | 0.66 | 14.44 | 0 | 0 | 0 | 0 | 0.52 | 0.38 | 0.43 | 0.08 | 0 | 0 | 0 |
| Return on equity % | 0 | 3.80 | -17.61 | -14.95 | -12.21 | -47.78 | -18.08 | -65.66 | -155.73 | 0 | 0 | 0 | 0 | -7.73 | 24.35 | -2.48 | 37.26 | 15.15 | 9.60 | 6.01 |
Zenotech Laboratories Ltd Ratios
The Zenotech Laboratories Ltd Ratios page provides a complete fundamental analysis of Zenotech Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Zenotech Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Zenotech Laboratories Ltd (NSE: , BSE: 532039) is currently trading at ₹42.84, with a market capitalization of ₹2.56B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Zenotech Laboratories Ltd remains a key stock for fundamental analysis using Zenotech Laboratories Ltd Ratios.
Zenotech Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Zenotech Laboratories Ltd P/E ratio currently stands at 56.45, making it one of the most tracked metrics in Zenotech Laboratories Ltd Ratios.
Historically, the Zenotech Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2024: 56.45
- 2023: 43.47
- 2022: 24.79
- 2021: 13.86
- 2020: 0
The rising Zenotech Laboratories Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Zenotech Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.30.
Historical P/B trend:
- 2024: 3.30
- 2023: 3.98
- 2022: 3.49
- 2021: 4.35
Zenotech Laboratories Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Zenotech Laboratories Ltd P/S ratio currently stands at 8.13, an important part of Zenotech Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 8.13
- 2023: 9.81
- 2022: 7.49
- 2021: 9.46
A stable or declining Zenotech Laboratories Ltd P/S ratio indicates cautious market sentiment.
Zenotech Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Zenotech Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 29.08.
Historical Zenotech Laboratories Ltd Price to Cash Flow Ratio:
- 2024: 29.08
- 2023: 28.26
- 2022: 13.73
- 2021: 18.57
- 2020: 50.28
The rising Zenotech Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.
Zenotech Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Zenotech Laboratories Ltd EV currently stands at ₹2.9B, representing the total company valuation including debt.
Historical EV trend:
- 2024: 2.9B
- 2023: 3.41B
- 2022: 2.76B
- 2021: 3.11B
Zenotech Laboratories Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Zenotech Laboratories Ltd EV/EBITDA ratio is currently 27.97, a key metric in Zenotech Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 27.97
- 2023: 25.56
- 2022: 16.47
- 2021: 23.14
Higher Zenotech Laboratories Ltd EV/EBITDA suggests premium valuation.
Zenotech Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Zenotech Laboratories Ltd D/E ratio is currently 0, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0.08
Zenotech Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Zenotech Laboratories Ltd ROE currently stands at 6.01%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 6.01
- 2023: 9.60
- 2022: 15.15
- 2021: 37.26
Declining ROE indicates pressure on profitability.
Zenotech Laboratories Ltd Ratios Analysis Summary
The Zenotech Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Zenotech Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Zenotech Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800